{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:43:07Z","timestamp":1787020987276,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100019274","name":"National Institute of Mental Health and Neurosciences","doi-asserted-by":"publisher","award":["D43 TW010037"],"award-info":[{"award-number":["D43 TW010037"]}],"id":[{"id":"10.13039\/100019274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Injection Drug use is associated with increased HIV risk behaviour that may result in the transmission of HIV and poor access to HIV prevention and treatment. In 2020, Uganda introduced the \u2018medication for opioid use disorder (MOUD) treatment\u2019 for People who inject drugs (PWID). We analysed the 12-month retention and associated factors among PWID enrolled on MOUD treatment in Kampala, Uganda.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of 343 PWID with OUD who completed 14 days of methadone induction from September 2020 to July 2022. Retention was defined as the number of individuals still in the programme divided by the total number enrolled, computed at 3-, 6-, 9-, and 12 months using lifetable and Kaplan-Meier survival analyses. Cox proportional regression analyses were conducted to assess factors associated with retention in the programme in the first 12 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 243 (71%) of 343 participants stabilized at a methadone dose of 60\u00a0mg or more. The majority of participants were males (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009284, 82.8%), and the median (interquartile range, IQR) age was 31 (26\u201338) years. Most participants (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009276, 80.5%) lived 5\u00a0km or more away from the MOUD clinic. Thirty (8.8%) were HIV-positive, 52 (15.7%) had a major mental illness and 96 (27.9%) had a history of taking alcohol three months before enrollment. The cumulative retention significantly declined from 83.4% (95%CI\u2009=\u200979.0\u201387.0) at 3months to 71.9% (95%CI\u2009=\u200967.2\u201376.6) at 6months, 64% 95%CI\u2009=\u200958.7\u201368.9) at 9months, and 55.2%; 95% CI (49.8\u201360.3% at 12months. The 12-month retention was significantly higher for participants on methadone doses of 60\u00a0mg or more (adj.HR\u2009=\u20092.1, 95%CI\u2009=\u20091.41\u20133.22), while participants resident within 5\u00a0km of the MOUD clinic were 4.9 times more likely to be retained at 12 months, compared to those residing 5\u00a0km or more, (adj. HR\u2009=\u20094.81, 95%CI\u2009=\u20091.54-15). Other factors, including predisposing, need, and enabling factors, were not associated with retention.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study demonstrates acceptable 12-month retention rates for people who inject drugs, comparable to previous studies done in both developing and developed countries. Sustaining and improving retention may require enhanced scaling up of MOUD dose to an optimal level in the first 14 days and reducing the distance between participant locale and MOUD clinics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-024-00468-4","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T07:02:38Z","timestamp":1715756558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Retention of people who inject drugs enrolled in a \u2018medications for opioid use disorder\u2019 (MOUD) programme in Uganda"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0727-3322","authenticated-orcid":false,"given":"Peter","family":"Mudiope","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian Byamah","family":"Mutamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Komuhangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Nangendo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Alamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Mathers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick","family":"Makumbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhoda","family":"Wanyenze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"issue":"5","key":"468_CR1","doi-asserted-by":"publisher","first-page":"e659","DOI":"10.1016\/S2214-109X(23)00057-8","volume":"11","author":"L Degenhardt","year":"2023","unstructured":"Degenhardt L, Webb P, Colledge-Frisby S, Ireland J, Wheeler A, Ottaviano S, et al. Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review. Lancet Glob Health. 2023;11(5):e659\u201372.","journal-title":"Lancet Glob Health"},{"key":"468_CR2","unstructured":"UNODC. World Drug Report 2023. United Nations publication; 2023."},{"issue":"8","key":"468_CR3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S2215-0366(22)00159-6","volume":"9","author":"V Haldane","year":"2022","unstructured":"Haldane V, Jung A-S, De Foo C, Shrestha P, Urdaneta E, Turk E, et al. Integrating HIV and substance misuse services: a person-centred approach grounded in human rights. Lancet Psychiatry. 2022;9(8):676\u201388.","journal-title":"Lancet Psychiatry"},{"issue":"9719","key":"468_CR4","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(10)60232-2","volume":"375","author":"BM Mathers","year":"2010","unstructured":"Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375(9719):1014\u201328.","journal-title":"Lancet"},{"issue":"2","key":"468_CR5","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/09540120802001705","volume":"21","author":"CA Mellins","year":"2009","unstructured":"Mellins CA, Havens JF, McDonnell C, Lichtenstein C, Uldall K, Chesney M, et al. Adherence to antiretroviral medications and medical care in HIV-infected adults diagnosed with mental and substance abuse disorders. AIDS Care. 2009;21(2):168\u201377.","journal-title":"AIDS Care"},{"key":"468_CR6","unstructured":"Rhoda K, Wanyenze G, Kiwanuka G, Musinguzi Z, Nampewo P, Kyambadde G, Pande et al. HIV AND AIDS LEGAL ENVIRONMENT ASSESSMENT FOR KEY POPULATIONS UGANDA AIDS COMMISSION; AUGUST 2022."},{"key":"468_CR7","first-page":"1","volume-title":"Rights and drugs\u2014harm reduction, decriminalization and zero discrimination for people who use drugs","author":"Health","year":"2019","unstructured":"UNAIDS, Health. Rights and drugs\u2014harm reduction, decriminalization and zero discrimination for people who use drugs. Geneva, Switzerland: UNAIDS; 2019. pp. 1\u201368."},{"issue":"5","key":"468_CR8","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.jana.2017.05.009","volume":"28","author":"L Barajas-Nava","year":"2017","unstructured":"Barajas-Nava L. Oral substitution treatment of injecting opioid users for prevention of HIV infection. J Assoc Nurses AIDS Care. 2017;28(5):832\u20133.","journal-title":"J Assoc Nurses AIDS Care"},{"issue":"3","key":"468_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/10550887.2012.694598","volume":"31","author":"G Bart","year":"2012","unstructured":"Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31(3):207\u201325.","journal-title":"J Addict Dis"},{"key":"468_CR10","unstructured":"Karki P, Shrestha R, Huedo-Medina TB, Copenhaver M. The impact of methadone maintenance treatment on HIV risk behaviors among high-risk injection drug users: a systematic review. Evidence-based medicine & public health. 2016;2."},{"key":"468_CR11","unstructured":"WHO(a). WHO, UNODC, UNAIDS technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users \u2013 2012 revision2012."},{"key":"468_CR12","unstructured":"Organization WH. Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations. World Health Organization; 2022."},{"key":"468_CR13","doi-asserted-by":"crossref","unstructured":"Colledge-Frisby S, Ottaviano S, Webb P, Grebely J, Wheeler A, Cunningham EB et al. Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review. Lancet Global Health. 2023.","DOI":"10.1016\/S2214-109X(23)00058-X"},{"key":"468_CR14","doi-asserted-by":"publisher","first-page":"1139307","DOI":"10.3389\/fpsyt.2023.1139307","volume":"14","author":"N Radfar","year":"2023","unstructured":"Radfar N, Radfar SR, Mohammadi F, Azimi A, Amirkafi A, Tehrani-Banihashemi A. Retention rate in methadone maintenance treatment and factors associated among referred patients from the compulsory residential centers compared to voluntary patients. Front Psychiatry. 2023;14:1139307.","journal-title":"Front Psychiatry"},{"issue":"1","key":"468_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13722-020-00186-7","volume":"15","author":"A Scheibe","year":"2020","unstructured":"Scheibe A, Shelly S, Gerardy T, von Homeyer Z, Schneider A, Padayachee K, et al. Six-month retention and changes in quality of life and substance use from a low-threshold methadone maintenance therapy programme in Durban, South Africa. Addict Sci Clin Pract. 2020;15(1):13.","journal-title":"Addict Sci Clin Pract"},{"issue":"3","key":"468_CR16","doi-asserted-by":"publisher","first-page":"e29121","DOI":"10.5812\/ijhrba.29121","volume":"5","author":"M Sheikh Fathollahi","year":"2016","unstructured":"Sheikh Fathollahi M, Torkashvand F, Najmeddin H, Rezaeian M. Predictors of one-year Retention in Methadone Maintenance Treatment (MMT) in Iran, Rafsanjan. Int J High Risk Behav Addict. 2016;5(3):e29121.","journal-title":"Int J High Risk Behav Addict"},{"key":"468_CR17","unstructured":"MoH(a). Technical Guidelines For Universal Access to HIV Prevention, Treatment and Care for People who Use Alcohol, Drugs, and Other Substances. September 2019."},{"key":"468_CR18","volume-title":"Uganda Harm Reduction Network. Needle and syringe program demonstration","author":"UHRN","year":"2018","unstructured":"UHRN. Uganda Harm Reduction Network. Needle and syringe program demonstration. Uganda: Kampala; 2018."},{"issue":"20","key":"468_CR19","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1001\/jama.2020.4104","volume":"323","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE. Diagnosis and treatment of opioid use disorder in 2020. JAMA. 2020;323(20):2082\u20133.","journal-title":"JAMA"},{"issue":"3","key":"468_CR20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/CNQ.0000000000000262","volume":"42","author":"LJ Canamo","year":"2019","unstructured":"Canamo LJ, Tronco NB. Clinical opioid withdrawal scale (COWS): implementation and outcomes. Crit Care Nurs Q. 2019;42(3):222\u20136.","journal-title":"Crit Care Nurs Q"},{"issue":"1\u20132","key":"468_CR21","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.drugalcdep.2009.07.001","volume":"105","author":"DA Tompkins","year":"2009","unstructured":"Tompkins DA, Bigelow GE, Harrison JA, Johnson RE, Fudala PJ, Strain EC. Concurrent validation of the clinical opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend. 2009;105(1\u20132):154\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"468_CR22","first-page":"1070","volume":"295","author":"MA Kling","year":"2000","unstructured":"Kling MA, Carson RE, Borg L, Zametkin A, Matochik JA, Schluger J, et al. Opioid receptor imaging with positron emission tomography and [18F] cyclofoxy in long-term, methadone-treated former heroin addicts. J Pharmacol Exp Ther. 2000;295(3):1070\u20136.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"468_CR23","doi-asserted-by":"publisher","first-page":"423","DOI":"10.15288\/jsa.1995.56.423","volume":"56","author":"MJ Bohn","year":"1995","unstructured":"Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 1995;56(4):423\u201332.","journal-title":"J Stud Alcohol"},{"key":"468_CR24","unstructured":"Metameasure Limited. The MethaMeasure System 2006 https:\/\/methameasure.co.uk\/about-us\/."},{"issue":"4","key":"468_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/archpsyc.57.4.395","volume":"57","author":"KL Preston","year":"2000","unstructured":"Preston KL, Umbricht A, Epstein DH. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch Gen Psychiatry. 2000;57(4):395\u2013404.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"468_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1177\/002204269702700205","volume":"27","author":"DD Simpson","year":"1997","unstructured":"Simpson DD, Joe GW, LR C, Dansereau DF. Strategies for improving methadone treatment process and outcomes. J Drug Issues. 1997;27(2):239\u201360.","journal-title":"J Drug Issues"},{"issue":"1","key":"468_CR27","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/add.12303","volume":"109","author":"J Feelemyer","year":"2014","unstructured":"Feelemyer J, Des Jarlais D, Arasteh K, Abdul-Quader AS, Hagan H. Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review. Addiction. 2014;109(1):20\u201332.","journal-title":"Addiction"},{"issue":"3","key":"468_CR28","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.drugalcdep.2010.06.013","volume":"112","author":"FJ Eiroa-Orosa","year":"2010","unstructured":"Eiroa-Orosa FJ, Haasen C, Verthein U, Dilg C, Schafer I, Reimer J. Benzodiazepine use among patients in heroin-assisted vs. methadone maintenance treatment: findings of the German randomized controlled trial. Drug Alcohol Depend. 2010;112(3):226\u201333.","journal-title":"Drug Alcohol Depend"},{"key":"468_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1471-244X-11-81","volume":"11","author":"L Ohlin","year":"2011","unstructured":"Ohlin L, Hesse M, Fridell M, Tatting P. Poly-substance use and antisocial personality traits at admission predict cumulative retention in a buprenorphine programme with mandatory work and high compliance profile. BMC Psychiatry. 2011;11:81.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"468_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0376-8716(96)01230-6","volume":"41","author":"M Torrens","year":"1996","unstructured":"Torrens M, Castillo C, Perez-Sola V. Retention in a low-threshold methadone maintenance program. Drug Alcohol Depend. 1996;41(1):55\u20139.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"468_CR31","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","volume":"35","author":"C Timko","year":"2016","unstructured":"Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22\u201335.","journal-title":"J Addict Dis"},{"issue":"3","key":"468_CR32","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.drugalcdep.2005.11.020","volume":"83","author":"SW Villafranca","year":"2006","unstructured":"Villafranca SW, McKellar JD, Trafton JA, Humphreys K. Predictors of retention in methadone programs: a signal detection analysis. Drug Alcohol Depend. 2006;83(3):218\u201324.","journal-title":"Drug Alcohol Depend"},{"key":"468_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jsat.2018.07.006","volume":"93","author":"S Amiri","year":"2018","unstructured":"Amiri S, Lutz R, Soc\u00edas ME, McDonell MG, Roll JM, Amram O. Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington. J Subst Abuse Treat. 2018;93:26\u201330.","journal-title":"J Subst Abuse Treat"},{"issue":"10279","key":"468_CR34","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/S0140-6736(21)00391-3","volume":"397","author":"SL Hodder","year":"2021","unstructured":"Hodder SL, Feinberg J, Strathdee SA, Shoptaw S, Altice FL, Ortenzio L, et al. The opioid crisis and HIV in the USA: deadly synergies. Lancet. 2021;397(10279):1139\u201350.","journal-title":"Lancet"},{"key":"468_CR35","unstructured":"Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, programs, services, and outcome. pringer-Verlag Publishing\/Springer Nature; 1991."},{"issue":"4","key":"468_CR36","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1037\/adb0000090","volume":"29","author":"SL Proctor","year":"2015","unstructured":"Proctor SL, Copeland AL, Kopak AM, Hoffmann NG, Herschman PL, Polukhina N. Predictors of patient retention in methadone maintenance treatment. Psychol Addict Behav. 2015;29(4):906.","journal-title":"Psychol Addict Behav"},{"issue":"3","key":"468_CR37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jsat.2011.07.009","volume":"42","author":"R Sarasvita","year":"2012","unstructured":"Sarasvita R, Tonkin A, Utomo B, Ali R. Predictive factors for treatment retention in methadone programs in Indonesia. J Subst Abuse Treat. 2012;42(3):239\u201346.","journal-title":"J Subst Abuse Treat"},{"key":"468_CR38","unstructured":"Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, programs, services, and outcome. Springer Science & Business Media; 2012."},{"issue":"3","key":"468_CR39","first-page":"208","volume":"9","author":"LA Aday","year":"1974","unstructured":"Aday LA, Andersen R. A framework for the study of access to medical care. Health Serv Res. 1974;9(3):208.","journal-title":"Health Serv Res"},{"key":"468_CR40","unstructured":"Aday LA, Begley CE, Lairson DR, Slater CH, Richard AJ, Montoya ID. A Framework for assessing the effectiveness, efficiency, and equity of behavioral Healthcare. THE AMERICAN JOURNAL OF MANAGED CARE; 1999."}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00468-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-024-00468-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00468-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T07:07:45Z","timestamp":1715756865000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-024-00468-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["468"],"URL":"https:\/\/doi.org\/10.1186\/s13722-024-00468-4","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"1 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This evaluation was approved by the Makerere University School of Public Health, Higher degrees Research and Ethics Committee, the Uganda National Council of Science and Technology (UNCST), and the administration of Butabika Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}